So sánh sự biểu hiện PD-L1 trong ung thư biểu mô tế bào vảy nguyên phát không xác định và ung thư biểu mô tế bào vảy vùng hầu họng
Tóm tắt
Sự hình thành khối u của ung thư biểu mô tế bào vảy nguyên phát không xác định (SCCUP) ở vùng đầu và cổ vẫn chưa được làm sáng tỏ, trong khi tỷ lệ sống sót thấp và các lựa chọn điều trị hạn chế tạo ra một thách thức nghiêm trọng. Mục tiêu của dự án này là điều tra các đặc điểm miễn dịch của SCCUP và so sánh chúng với ung thư biểu mô tế bào vảy vùng hầu họng (OPSCC).
Sự biểu hiện PD-L1 (TC) đã được kiểm tra bằng phương pháp nhuộm miễn dịch trong 50 di căn hạch bạch huyết của SCCUP và 47 mẫu nguyên phát của OPSCC. Sự xâm nhập của tế bào lympho CD3 + và CD8 + được đo đếm trong 5 trường hợp có độ phóng đại cao. Sự biểu hiện của p16 và HPV ISH cũng được đánh giá.
SCCUP cho thấy sự biểu hiện PD-L1 cao hơn một cách đáng kể so với OPSCC. Trong các SCCUP âm tính với p16, PD-L1 chứng tỏ là một yếu tố tiên lượng độc lập để ưu tiên các bệnh nhân có nguy cơ cao.
Các khác biệt miễn dịch giữa SCCUP và OPSCC đã được phát hiện. Sự biểu hiện PD-L1 cao hơn ở SCCUP có thể tạo điều kiện thuận lợi cho việc đánh giá thêm liệu pháp ức chế điểm kiểm soát.
Từ khóa
Tài liệu tham khảo
Global Burden of Disease Cancer, C et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 5(12):1749–1768
Varadhachary G (2013) New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res 19(15):4027–4033
Adjei Boakye E et al (2018) Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. JAMA otolaryngology. Head Neck Surge 144(8):727–737
Conway AM et al (2019) Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the “U” out of “CUP.” Br J Cancer 120(2):141–153
Rassy E, Pavlidis N (2019) The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 61:139–141
Mayordomo JI et al (1993) Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 79(5):321–324
Kolling S et al (2020) “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”? Front Oncol 9:1546–1546
Sivars L et al (2016) Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin oncol 5(6):671–674
Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12(4):418–425
Eskander A, Ghanem T, Agrawal A (2018) AHNS Series: do you know your guidelines? Guideline recommendations for head and neck cancer of unknown primary site. Head Neck 40(3):614–621
Rassy E, Nicolai P, Pavlidis N (2019) Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. Head Neck 41(10):3700–3711
Takada K (2012) Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Semin Cancer Biol 22(2):162–165
Sivars L et al (2016) Human papillomavirus as a diagnostic and prognostic tool in cancer of unknown primary in the head and neck region. Anticancer Res 36(2):487–493
Müller von der Grün J et al (2017) Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site—current status and challenges. Radiat Oncol (London, England) 12(1):82–82
Davalos V, Esteller M (2020) Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP). EMBO Mol Med 12(7):e12685–e12685
Burtness B, et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England) 394(10212):1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7
Kansy BA et al (2017) PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 77(22):6353–6364
Mandal R et al (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1(17):e89829
Wu Y et al (2019) PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol 10:2022–2022
Cohen EEW et al (2019) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184–184
Binnewies M et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550
Elbehi AM et al (2020) Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncol 109:104977
Patel JJ et al (2020) Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck 42(4):774–786
Haratani K et al (2019) Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 7(1):251
Dong P et al (2018) Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol 8:386
Simsek M, Tekin SB, Bilici M (2019) Immunological agents used in cancer treatment. Eurasian J Med 51(1):90–94
Alsahafi E et al (2019) Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10(8):540
Sun L et al (2020) Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 10(1):2083
Hemminki K et al (2016) Age-dependent metastatic spread and survival: cancer of unknown primary as a model. Sci Rep 6:23725–23725
Hermans KEPE et al (2021) Alcohol consumption, cigarette smoking and cancer of unknown primary risk: Results from the Netherlands Cohort Study. Int J Cancer 141(7):1586–1597
Gatalica Z et al (2018) Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer 94:179–186
Cohen EE et al (2016) American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin 66(3):203–239
Elrefaey S et al (2014) HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngolog Ital 34(5):299–309
Ross JS et al (2020) Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26:e394–e402
Motz K et al (2016) Changes in unknown primary squamous cell carcinoma of the head and neck at initial presentation in the era of human papillomavirus. JAMA Otolaryngol-Head Neck Surg 142(3):223–228
Cummings MA et al (2021) Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry. Ann Transl Med 9(4):284
Reuschenbach M et al (2019) A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med 8(4):1908–1918
Bosch FX et al (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31 Suppl 7(Suppl 7):H1–H31
Lanzer M et al (2015) Unknown primary of the head and neck: A long-term follow-up. J Craniomaxillofac Surg 43(4):574–579
Sprave T et al (2020) Radiotherapeutic management of cervical lymph node metastases from an unknown primary site—experiences from a large cohort treated with modern radiation techniques. Radiat Oncol 15(1):80
Chung CH et al (2014) p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32(35):3930–3938
Seiwert TY et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965
Lei X et al (2020) Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett 470:126–133
Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542–e551